TML-OSE-22

TML-OSE-22 is a preclinical-stage, ready-to-use (RTU) injectable formulation of a proton-pump inhibitor (PPI), likely esomeprazole, developed by Themis Medicare. As part of Themis's focus on Novel Drug Delivery Systems (NDDS), this product is designed as a stable, pre-mixed solution for intravenous administration, eliminating the need for the manual reconstitution of lyophilized powder typically required for PPIs. This "ready-to-use" format is intended to streamline clinical workflows, reduce the risk of dosing errors, and minimize potential microbial contamination in hospital settings. The active ingredient functions by irreversibly inhibiting the H+/K+-ATPase enzyme system (the gastric acid pump) in the parietal cells of the stomach, thereby providing potent and long-lasting suppression of gastric acid secretion. TML-OSE-22 is being developed for conditions where rapid acid suppression is required and oral administration is not feasible, such as severe gastroesophageal reflux disease (GERD) and peptic ulcer disease.

Other names

Esomeprazole ready-to-use injectionThemis Medicare PPI injection